Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Douglas Zipes MD
Douglas P. Zipes MD Editor-in-Chief
Paul Thompson MD
Paul D. Thompson MD Advisory Board
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI
J. William McEvoy MB BCh BAO, MEd, MHS, PhD, FRCPI Advisory Board
See All Experts
featured
Published in Cardiology

Journal Scan / Research · July 28, 2016

Atherothrombotic Risk Assessment Assists Decision Making Regarding Vorapaxar in MI Patients

Circulation

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Benjamin Scirica MD

Circulation
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Prior Myocardial Infarction
Circulation 2016 Jul 26;[EPub Ahead of Print], EA Bohula, MP Bonaca, E Braunwald, PE Aylward, R Corbalan, GM De Ferrari, P He, BS Lewis, PA Merlini, SA Murphy, MS Sabatine, BM Scirica, DA Morrow

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated